Company news

Clene Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Clene Announces 1-for-20 Reverse Stock Split

July 8, 2024

Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference

June 23, 2024

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

June 20, 2024

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

June 17, 2024

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 27, 2024

Clene to Present at Upcoming May Conferences

May 13, 2024

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

May 7, 2024

Evidence for Clene’s CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

April 15, 2024

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

March 14, 2024

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

March 12, 2024

Clene to Present at the 36th Annual ROTH Conference

March 6, 2024

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

February 28, 2024

Clene Reports Significant Survival Benefit With CNM-Au8® Treatment in ALS EAP Compassionate Use Programs

February 21, 2024

Clene Inc. announces positive results from CNM-Au8 results from MS trial

February 4, 2024

Clene Reports Significant Improvement in Vision and Cognition With CNM-Au8® Treatment in VISIONARY-MS Trial Long-Term Open Label Extension

January 7, 2024

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

December 20, 2023

Clene Provides Update on ALS Clinical Development Meeting With FDA

December 20, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

December 13, 2023

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

November 6, 2023

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

October 4, 2023

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

September 27, 2023

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

September 24, 2023

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

September 24, 2023

Clene to Present at Upcoming September Conferences

August 29, 2023

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

August 28, 2023

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

August 13, 2023

Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference

August 1, 2023

Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine

June 25, 2023

Clene Welcomes New Shareholder Base and Announces Closing of Underwritten Public Offering of $40 Million

June 20, 2023

Clene Announces Pricing of $40 Million Public Offering

June 15, 2023

Clene to Participate in the Maxim Group Virtual Healthcare Conference

June 14, 2023

Clene’s CNM-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (NfL) levels in the HEALEY ALS Platform Trial

June 14, 2023

Clene Announces Launch of Proposed Public Offering

June 14, 2023

Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis

May 24, 2023

Clene Reports First Quarter 2023 Financial Results and Recent Operating Highlights

May 11, 2023

ALS and MS Clinical Data from Clene’s CNM-Au8® Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

April 24, 2023

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting

April 10, 2023

Clene Appoints Neurology Expert to Executive Team

March 15, 2023

Clene Reports Full Year 2022 Financial Results and Recent Operating Highlights

March 12, 2023

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial

March 8, 2023

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial

March 7, 2023

Clene Nanomedicine to Participate in Roth’s 35th Annual Healthcare Conference and Renmark Virtual Non-Deal Roadshow Series

March 6, 2023

New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial

March 5, 2023

Clene Announces Updated VISIONARY-MS Phase 2 Trial Data Presented at 2023 ACTRIMS Forum Show CNM-Au8® Demonstrated Significant Improvements in Clinical Outcomes, Brain Structure, and Visual System

February 26, 2023

Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity

February 12, 2023

Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23

January 10, 2023

Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg

December 26, 2022

Clene Announces Closing of $5 Million Debt Facility from the State of Maryland

December 11, 2022

VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies

November 27, 2022

Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights

November 6, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 44 decks. Every deck is listed under its year.